Pemvidutide is a lower-profile name than some of the weight-loss drugs in the news, but it's been through more real human testing than most peptides people search for. It's also a good example of what honest, unfinished evidence actually looks like — because its biggest trial to date produced a genuinely mixed result.
What pemvidutide actually is
Pemvidutide (its lab code is ALT-801) is an experimental medicine being developed by a company called Altimmune. It's a dual agonist — an *agonist* is something that switches a receptor on, like a key in a lock. Pemvidutide turns two locks at once: GLP-1 and glucagon.
- GLP-1 is a gut hormone — a messenger your gut releases when you eat. It tells your brain you're full, slows how fast food leaves your stomach, and helps control blood sugar. This is the same signal behind drugs like semaglutide.
- Glucagon is a different hormone, and it's the interesting half. It acts directly on your liver, nudging it to burn fat instead of making and storing more of it.
That second half is the whole point of the design. Losing weight tends to clear fat out of your liver on its own — but the glucagon signal is meant to go after liver fat directly, not just as a side effect of getting smaller. That's why pemvidutide has been aimed at fatty liver disease as much as at obesity.
What it's studied for
- Obesity and weight loss — tested in a mid-stage trial called MOMENTUM
- MASH and MASLD (fatty liver disease) — the main focus; these are conditions where fat builds up in the liver, and in MASH it also causes inflammation and scarring
- Alcohol-related liver disease and alcohol use disorder — newer trials, still running, no results yet
Those last two are worth a note: GLP-1-type drugs unexpectedly seem to reduce some people's interest in drinking, and researchers are now testing that properly rather than guessing. It's an open question, not a finding.
Where it actually is in testing
Drugs move through stages. Phase 1 checks basic safety in a small group. Phase 2 looks for early signs it works. Phase 3 is the big final test regulators need before approving anything. Pemvidutide has not completed Phase 3 — it hasn't started one.
| Trial | What it looked at | Status |
|---|---|---|
| Phase 1 (NCT04561245) | Basic safety in overweight and obese volunteers | Completed |
| Phase 1 (NCT05006885) and its extension (NCT05292911) | Liver fat in people with fatty liver disease | Completed and published |
| Phase 2 — MOMENTUM (NCT05295875) | Obesity, about 391 adults, 48 weeks | Completed |
| Phase 2b — IMPACT (NCT05989711) | MASH with liver scarring, 212 adults | Completed and published — mixed result |
| Phase 2 — RESTORE (NCT07009860) | Alcohol-associated liver disease | Recruiting — no results |
| Phase 2 — RECLAIM (NCT06987513) | Alcohol use disorder in people with obesity or overweight | Running — no results |
What the evidence really shows — including the miss
The most important trial is IMPACT, a Phase 2b study published in *The Lancet* in 2025. It was randomized (people sorted into groups by chance) and placebo-controlled (some got a dummy injection, and nobody knew who) — the design you want. It had two main goals, and this is where honesty matters:
- Goal one — clearing up the MASH itself: hit. Around half or more of the people on pemvidutide had their MASH resolve without their scarring getting worse, compared with about 1 in 5 on placebo. That's a clear, statistically solid win.
- Goal two — improving the liver scarring (fibrosis): missed. People on pemvidutide didn't do meaningfully better than placebo on this at 24 weeks. The difference was small enough that it could easily have been chance.
That second point is the one that gets dropped from hype posts. Fibrosis — scarring — is the thing that actually predicts whether someone's liver will fail. Calming the inflammation is good news. Not moving the scarring is a real limitation, and the trial's own authors said so and called for longer studies. Earlier, smaller trials did show large drops in liver fat and meaningful weight loss, and side effects were mostly mild-to-moderate nausea.
So the fair summary is: real human evidence, genuinely encouraging in parts, incomplete and partly disappointing in others, and nowhere near approval.
What the research points to
- MASH resolution in a published, randomized, placebo-controlled Phase 2b trial
- Large reductions in liver fat and meaningful weight loss in earlier trials
- A thoughtful mechanism — a liver-directed signal on top of the familiar appetite one
- Mostly mild-to-moderate side effects reported so far, mainly nausea
What it does NOT prove
- That it improves liver scarring — its biggest trial specifically failed to show that
- That it's approved, finished, or available — it is none of those
- That it's safe or effective long-term; the trials that would show that haven't been run
- That anything sold online under this name is the real molecule or safe to use
Who talks about it — and why to be careful
Pemvidutide shows up in two crowds: people following biotech stocks, and people in weight-loss and 'research peptide' communities hunting for the next thing before it's approved. Neither crowd is a safety check. Investors are interested in whether a trial moves a share price, which is a completely different question from whether a vial is safe to put in your body. And the fact that a drug has real published research behind it doesn't transfer any of that legitimacy to an unregulated seller using its name.
What this does not mean
- This does not mean pemvidutide is available as a treatment — it's investigational and not approved anywhere.
- This does not mean it improves liver scarring; its largest published trial specifically did not show that.
- This does not mean online 'research' versions are the real drug or safe to use.
- This is general education, not medical advice or a recommendation to use pemvidutide.